Nervotec is the world’s first provider of HaaS (Healthcare as a Service), a software only solution that measures and analyses physiological biomarkers remotely and contactlessly across multiple mobile platforms.

Nervotec’s proprietary video-based technology enables the rapid measurement of physiological biomarkers with medical grade accuracies, while creating actionable insights on stress and heart health.

Nervotec’s solutions are used in professional sports, construction, insurance, healthcare, and governmental sectors worldwide.

Through its technologies, Nervotec is transforming the way people access healthcare, truly enabling healthcare anywhere.

SunGreenH2 is an award-winning startup building the world’s highest performance water electrolysis technology
that doubles (2x) production of green hydrogen while significantly reducing platinum group metal loading and energy consumption. Our proprietary component technology is the result of over 10 years of research in nanotechnology and electrochemistry. The company is currently working with leading electrolyser manufacturers and hydrogen end users to bring its products to market.

We develop automatic speech recognition (ASR) SaaS solutions. Our ASR engines are developed by our Co-founder, Ian Lane, one of the best R&D teams at Carnegie Mellon University. Our recent product, Auris Edit, aims to make digital content accessible to the world.
Auris Edit enables content creators to easily create caption, transcription and inserting foreign subtitles, reducing their 50% of post-editing time. Creators can spend more time on contents creation rather than on less creative editing processes.
Our primary target is light users like mid-entry level YouTubers, or freelancers who help top YouTubers to add captions/subtitles. YouTube has over 50m content creators, and only with YouTube, we expect that the demand is high.
Captions/Subtitles are a must-have feature for content creators because 60% of YouTube views are from non-native English speakers, say people in South East Asia!
So Auris Edit will first target Asian market making digital content accessible.

Acumen has developed AcuSeptTM — a novel, blood-based Sepsis Host Response test using sepsis-specific mRNA biomarkers — that can assist the doctos to detect sepsis in patients in 4-5 hrs, earlier and more accurately than current methods.

Intended Use:
AcuSeptTM generates diagnostic scores which fall in the range of either above or below a validated threshold level that determines the risk of sepsis. AcuSeptTM results are to be used in conjunction with clinical assessments and other laboratory findings as an aid to identify patients with low or high risk of infection and sepsis.

Clinical Utility:
・To differentiate patients with and without infection
・To differentiate patients with and without sepsis
・Can identify sepsis early

Ampotech develops internet of things (IoT) hardware and AI-enabled software to help businesses collect, analyze, and integrate electricity usage data from the built environment to deliver intelligent solutions and services. Launched in 2015 and headquartered in Singapore, Ampotech is supported by investors from the electronics, telecommunications, and deep tech sectors, with customers throughout the Asia Pacific region in industries such as energy & facility services, commercial real estate, manufacturing, and utilities.

Advent Access is a medical technology startup focused on end-stage renal disease management. A Stanford StartX company and spin-off from A*STAR, Advent’s mission is to pioneer innovations to significantly reduce dialysis cost and restore quality of life for kidney failure patients. The company’s first product is the av-Guardian™ – an award-winning implant technology that aims to improve vascular access reliability, enable less-painful self-cannulation and, in the long run, potentially reduce vascular access related hospitalizations. The av-Guardian™ forms a key component of Advent Access’ dialysis-machine agnostic platform to empower patients to perform hemodialysis independently, safely and more affordably – at home or in novel care environments.
For more information on Advent Access, please visit http://www.adventaccess.com/

At Craft Health, we are building a platform for 3D printed personalized healthcare. Possible applications include personalized nutrition, decentralized clinical trials, personalized medicine, and 3D printing for orphan drugs.

Since we launched in May 2019, we have:

・Hardware: In-house developed 3D printer specialized for nutraceuticals and pharmaceuticals. Our 3D printer is designed for Good Manufacturing Practice (GMP) and the 3D printing process does not involve heat or ultraviolet (UV) curing, enabling a wide range of active ingredients to be used.
・Software: 3D printing software
・3D printable formulations: A series of proprietary 3D printable formulations for different controlled released profiles (Immediate/sustained/delayed release) that can be combined in a single 3D printed tablet.
・Specialty products: Patent pending 3D printed capsule that converts once daily dosing to once weekly.

BioCheetah Pte Ltd (Co. Reg. No. 201803287H) is a Singapore-based, A*STAR-IMCB spin-off diagnostics company. It is primarily set up to develop and commercialize non-invasive, protein-based diagnostic applications. First diagnostic applications in development are based on the proprietary bladder cancer biomarkers and detection antibodies discovered and developed in IMCB by BioCheetah’s Scientific Founder (Prof. Jean-Paul Thiery) and the co-Founder/Chief Executive Officer (Dr. Kian-Chung Lee). Both Intellectual Property of bladder cancer biomarkers and detection antibodies are licensed from A*STAR. Products to be developed include professional use in-vitro diagnostic ELISA and Point-of-care test (POCT) kits. The kits will employ a novel multiplex urine-based biomarkers panel with high sensitivity and specificity for diagnosis and monitoring of bladder cancer. BioCheetah’s target markets are to encompass local and overseas public and private healthcare providers. BioCheetah is in the midst of building an ISO 13485 production facility at Block 79, JTC LaunchPad in Singapore, setting up its Quality Management System (QMS) for the purpose of development and manufacturing of its diagnostic products as well as in discussion with SingHealth and overseas hospitals for clinical validation of the to-be-developed bladder cancer diagnostic products.